Researchers at Texas A&M University have developed a microfluidic device that mimics the complex architecture of vasculature to better study blood clot treatments. The device includes channels with spirals, bends, and curves that are similar to those found in blood vessels, and which can influence blood clotting. Besides being biomimetic, the device is also faster and less expensive than existing blood clot testing technologies, and does not require a skilled technician to operate it.
Blood clots are involved in numerous diseases, from strokes to heart attacks and specific clotting disorders such as hemophilia. Researchers are therefore interested in studying factors that influence clotting and identifying new treatments to reduce or promote it.
tortuous shapes of blood vessels can influence the fluid dynamics of blood
flowing through them, and can activate or significantly influence blood clotting.
However, most devices used to study or detect blood clotting do not account for
this, and instead are based purely on the chemical mechanism underlying
not incorporate the flow through the naturally turning and twisting blood
vessels, which are physical regulators of blood clotting,” said Abhishek Jain,
a researcher involved in the study. “Therefore, the readouts from these current
static systems are not highly predictive, and often result in false positives
or false negatives.”
purpose is to model these complex curves and spirals and mimic a diseased vascular
microenvironment, so as to more accurately investigate blood clotting and
identify effective treatments for clotting disorders. The device allows clinicians
to measure platelet and fibrin content and coagulation in a blood sample
and could be used to test new
drugs intended to treat clotting disorders.
with existing chemical techniques to study blood clotting, the device can
provide a result very rapidly, taking just 10–15 minutes, and requires only a
small volume of blood. So far, the researchers have tested their device with
patients using an extracorporeal membrane oxygenation (ECMO) machine, for whom
blood clotting is a risk.
for error is essentially zero for these patients,” said Jain. “Therefore, it’s
imperative that all the tests, not just clotting tests, must work and provide
clinicians with quick and reliable information about their patient so they can
provide the best care possible.”
Study in Scientific Reports: Tortuosity-powered
microfluidic device for assessment of thrombosis and antithrombotic therapy in
more recommended stories
Ardena’s Expertise Helps New Treatment for Parkinson’s Disease
Ghent, Belgium 30 August 2021: Ardena,.
Inflatable Neurostimulator for Minimally Invasive Pain Control
Researchers at the University of Cambridge.
Quasiprobabilities Shed Light on Quantum Advantage
Quantum advantage is a hot topic,.
The Total Knockout: Towards Personalized Anesthesia
A team of researchers at the.
Localized Prostate Cancer Therapy: Interview with Shyam Natarajan, CEO of Avenda Health
Avenda Health, a medtech company based.
What innovations could shape the future of orthopaedics?
Lloyd Hines looks at how advances.
Bromelain Market to Exhibit Significant Incremental Dollar Opportunity During the Forecast Period
Derived from the pineapple plant, the.
High-Tech Contact Lenses May Replace Smart Phones
When Alexander Graham Bell brought us.
First Dedicated Pediatric and Neonatal Acute Dialysis Machine Released U.S.
Medtronic is releasing in the United.
ivWatch Monitors IV Placement Sites for Leakage, Now Cleared by FDA
ivWatch, a company based in Newport.